The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

You know the perfect party when you feel it. The right details certainly help - whether it’s flowers and overflowing champagne coupés or red Solo cups and balloons - but a great gathering always comes ...

A code of secrecy surrounds the drug’s prevalence on campuses and in sororities.” ...

Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...

Marines May Remove Troops With Skin Condition Affecting Mostly Black Men ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...

ABC News' Dr. Tara Narula shares what patients need to know. Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U ...